SILIQ
Valeant Pharmaceuticals Ireland Limited
Trademark Registered: 2019-07-23
Trademark Application Details
REGISTERED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 86396790 |
| Registration Number | 5813726 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Robert Gorman |
| Law Office Assigned | L10 |
| Employee Name | SPARER, ZACHARY R |
Timeline
| 2014-09-16 | Application Filed |
| 2015-07-14 | Published for Opposition |
| 2017-07-10 | Date of First Use |
| 2019-06-14 | Location: PUBLICATION AND ISSUE SECTION |
| 2019-07-23 | Status: Live/Registered |
| 2019-07-23 | Trademark Registered |
| 2019-07-25 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  VALEANT PHARMACEUTICALS IRELAND LIMITED |
| Entity Statement | LIMITED COMPANY |
| Address | 3013 LAKE DRIVE DUBLIN IE 47335 |
| Legal Entity Type | |
| Legal Entity State | IE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations, namely, pharmaceutical preparations used to treat chronic immune disorders, joint inflammation disorders and chronic inflammatory disorders; pharmaceutical preparations intended to treat psoriasis, psoriatic arthritis and asthma |
| GS0051 | Pharmaceutical preparations, namely, pharmaceutical preparations used to treat chronic immune disorders, joint inflammation disorders and chronic inflammatory disorders; pharmaceutical preparations intended to treat psoriasis, psoriatic arthritis and asthma |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2014-09-19 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2014-09-24 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2014-11-19 | 3 DOCK D:Assigned to Examiner |
| PRIORITY ACTION WRITTEN | 2014-11-20 | 4 CPRA R:Renewal |
| PRIORITY ACTION E-MAILED | 2014-11-20 | 5 GPRA F:First Action |
| NOTIFICATION OF PRIORITY ACTION E-MAILED | 2014-11-20 | 6 GPRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2015-05-13 | 7 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2015-05-13 | 8 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2015-05-13 | 9 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2015-05-15 | 10 CNSA P: |
| ASSIGNED TO LIE | 2015-06-06 | 11 ALIE A:Allowance for Publication |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2015-06-06 | 12 PREV O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2015-06-24 | 13 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2015-07-14 | 14 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2015-07-14 | 15 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2015-09-08 | 16 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2016-02-18 | 17 EEXT I:Incoming Correspondence |
| EXTENSION 1 FILED | 2016-02-18 | 18 EXT1 S: |
| EXTENSION 1 GRANTED | 2016-02-18 | 19 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2016-02-20 | 20 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2016-08-30 | 21 EEXT I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2016-09-17 | 22 AITU A:Allowance for Publication |
| EXTENSION 2 FILED | 2016-08-30 | 23 EXT2 S: |
| EXTENSION 2 GRANTED | 2016-09-17 | 24 EX2G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2016-09-20 | 25 EXRA E:E-Mail |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2017-01-25 | 26 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2017-01-25 | 27 ARAA I:Incoming Correspondence |
| TEAS EXTENSION RECEIVED | 2017-03-03 | 28 EEXT I:Incoming Correspondence |
| EXTENSION 3 FILED | 2017-03-03 | 29 EXT3 S: |
| EXTENSION 3 GRANTED | 2017-03-03 | 30 EX3G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2017-03-07 | 31 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2017-09-06 | 32 EEXT I:Incoming Correspondence |
| EXTENSION 4 FILED | 2017-09-06 | 33 EXT4 S: |
| EXTENSION 4 GRANTED | 2017-09-06 | 34 EX4G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2017-09-08 | 35 EXRA E:E-Mail |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2017-09-19 | 36 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2017-09-19 | 37 ARAA I:Incoming Correspondence |
| TEAS EXTENSION RECEIVED | 2018-03-06 | 38 EEXT I:Incoming Correspondence |
| EXTENSION 5 FILED | 2018-03-06 | 39 EXT5 S: |
| EXTENSION 5 GRANTED | 2018-03-06 | 40 EX5G S: |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2018-08-08 | 41 ASGN I:Incoming Correspondence |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-09-11 | 42 EXRA E:E-Mail |
| TEAS STATEMENT OF USE RECEIVED | 2018-09-10 | 43 EISU I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2019-02-14 | 44 AITU A:Allowance for Publication |
| ITU OFFICE ACTION ISSUED FOR STATEMENT OF USE | 2019-03-02 | 45 INCS O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-03-25 | 46 TROA I:Incoming Correspondence |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2019-03-27 | 47 ASGN I:Incoming Correspondence |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2019-05-29 | 48 ASGN I:Incoming Correspondence |
| USE AMENDMENT FILED | 2018-09-10 | 49 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2019-06-04 | 50 SUPC I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2019-06-14 | 51 CNPR P: |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2019-06-15 | 52 SUNA E:E-Mail |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2019-07-10 | 53 ASCK I:Incoming Correspondence |
| REGISTERED-PRINCIPAL REGISTER | 2019-07-23 | 54 R.PR A:Allowance for Publication |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2019-07-24 | 55 ASCK I:Incoming Correspondence |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2020-11-25 | 56 ASCK I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2022-08-22 | 57 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2022-08-22 | 58 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2022-08-22 | 59 TCCA I:Incoming Correspondence |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2022-12-14 | 60 ASCK I:Incoming Correspondence |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2022-12-28 | 61 ASCK I:Incoming Correspondence |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2023-01-18 | 62 ASCK I:Incoming Correspondence |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2023-02-08 | 63 ASCK I:Incoming Correspondence |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 SILIQ 88152405 5888704 Live/Registered |
Valeant Pharmaceuticals Ireland Limited 2018-10-12 |
SILIQ 88152405 5888704 Live/Registered |
BAUSCH HEALTH IRELAND LIMITED 2018-10-12 |
 SILIQ 86396790 5813726 Live/Registered |
VALEANT PHARMACEUTICALS IRELAND LIMITED 2014-09-16 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 